Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected (GX-ICON)

22 de setembro de 2026 atualizado por: Yi Du, First Affiliated Hospital of Guangxi Medical University

A Multicenter Prospective Diagnostic Accuracy Study of the 2022 International Criteria for Optic Neuritis and an Antibody-Stratified Adjunct in Acute or Subacute Visual Loss When Optic Neuritis Is Suspected in China

Optic neuritis is an important cause of acute or subacute visual loss. In clinical practice, optic neuritis must often be distinguished from other optic neuropathies, retinal diseases, anterior-segment or ocular media disorders, non-organic visual loss, and other mimics. The 2022 International Criteria for Optic Neuritis were developed to standardize the diagnosis of optic neuritis, but their performance in Chinese clinical settings, where aquaporin-4 immunoglobulin G positive and myelin oligodendrocyte glycoprotein immunoglobulin G positive optic neuritis are relatively common, remains uncertain.

This multicenter prospective observational study is enrolling patients with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis. The study is designed to evaluate the diagnostic performance of the 2022 International Criteria for Optic Neuritis alone and with an antibody-stratified adjunct. The index classifications will be compared with an expert-adjudicated reference-standard diagnosis. No experimental treatment is assigned by the study. All diagnostic tests and treatments are determined by the treating clinicians according to routine clinical care. Study data are collected using a structured protocol-defined case report form.

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

This multicenter prospective observational study evaluates the 2022 International Criteria for Optic Neuritis, alone and with an antibody-stratified adjunct, in patients initially suspected of having optic neuritis. Structured prospective data collection began on January 6, 2025. Each participant contributes one clinical episode. The cohort is not restricted to participants ultimately diagnosed with optic neuritis. Diagnostic testing and treatment are determined by the treating clinicians as part of routine care.

Baseline symptoms and ophthalmic findings are recorded using a structured electronic case report form. Available visual field, optical coherence tomography, magnetic resonance imaging, and laboratory findings are collected. Baseline and follow-up optical coherence tomography are encouraged when clinically feasible but are not required by study participation. Available follow-up findings can support reference-standard adjudication. Absence of follow-up optical coherence tomography alone does not exclude a participant from the primary analysis.

Both index strategies use baseline clinical data and eligible paraclinical information obtained within 3 months after symptom onset for the current episode, based on examination or sample collection dates. Later information will not revise either index classification. The 2022 criteria assign definite optic neuritis, possible optic neuritis, or not optic neuritis using prospectively recorded clinical findings, including actual color vision assessments rather than assumed abnormalities.

The antibody-stratified adjunct described in Table 2 of Liang and colleagues (2026) is applied only to participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the index window. Under that framework, acute or subacute visual loss with at least one objective finding consistent with optic neuropathy supports definite optic neuritis; without such an objective finding, the adjunct category is possible optic neuritis. The final index classification is the higher-certainty category assigned by the 2022 criteria or the adjunct, using the hierarchy definite optic neuritis, possible optic neuritis, then not optic neuritis. Participants without either qualifying positive antibody result retain their original 2022 criteria classification. Unavailable antibody results are not treated as negative.

Participants are followed for up to 6 months after enrollment whenever feasible. Reference-standard adjudication uses baseline information and available clinical course, repeat examinations, investigations, treatment response, and alternative diagnoses within this period. The target is whether the current episode represents optic neuritis, not merely whether an antibody-associated disease is present.

For each participant, two experts independently assess the case in two stages. In Stage 1, current and historical aquaporin-4 immunoglobulin G and myelin oligodendrocyte glycoprotein immunoglobulin G results, including directly revealing diagnostic labels, are withheld. Stage 1 judgments are recorded and locked before antibody disclosure. In Stage 2, the same experts reassess the case after receiving available antibody results and relevant assay information. Both stages use otherwise identical case information and the same information cutoff, no later than 6 months after enrollment. At each stage, cases are classified as optic neuritis, non-optic neuritis, or indeterminate. A third expert resolves disagreements under the corresponding information restrictions; Stage 1 disagreements are resolved before disclosure.

At both stages, experts are masked to the index classifications. Personnel assigning or verifying index classifications are masked to the expert reference diagnoses. Masking antibody results from experts does not remove those results from either index strategy. Index classifications and reference diagnoses are recorded separately and finalized before comparative analysis. Stage 2 full-information adjudication is the primary reference standard. Stage 1 provides a supplementary reference for sensitivity analyses and assessment of diagnostic changes after antibody disclosure. Initial agreement between experts is summarized at each stage using percentage agreement and Cohen's kappa.

The primary analysis treats definite optic neuritis as index-positive and not optic neuritis as index-negative; possible optic neuritis is excluded from this conditional binary analysis and reported separately. A secondary low-threshold analysis treats definite or possible optic neuritis as positive. Indeterminate reference diagnoses are excluded from the corresponding binary accuracy calculations but retained in reported category distributions. Definite-classification yield is also compared within the same reference-positive participants, retaining possible classifications as not definite. Newly upgraded cases are described according to their reference diagnoses. First-stage indeterminacy does not exclude a participant from second-stage analyses. Detailed outcome definitions are provided in the outcome measures section.

At initial public registration, recruitment was ongoing, and database lock, formal reference-standard adjudication, final index classification, and the primary diagnostic accuracy analysis had not occurred. The antibody-masked stage is an amendment-added assessment; full-information expert adjudication remains the primary reference standard.

Tipo de estudo

Observacional

Inscrição (Estimado)

500

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Recrutamento
        • The First Affiliated Hospital of Guangxi Medical University
        • Contato:
      • Nanning, Guangxi, China, 530005
        • Recrutamento
        • The Second Affiliated Hospital of Guangxi Medical University
        • Contato:
      • Nanning, Guangxi, China, 530001
        • Recrutamento
        • Guangxi Minzu Hospital
        • Contato:
      • Nanning, Guangxi, China, 530022
        • Recrutamento
        • Guangxi Jingliang Eye Hospital
        • Contato:
          • Mukun Zhao
          • Número de telefone: +86 771 7980630
      • Nanning, Guangxi, China, 530199
        • Recrutamento
        • Wuming Hospital of Guangxi Medical University
        • Contato:
          • Xiaoyuan Ma
          • Número de telefone: +86 771 6226473
        • Contato:
          • Yihua Huang
      • Qinzhou, Guangxi, China, 535000
        • Recrutamento
        • The Second People's Hospital of Qinzhou
        • Contato:
          • Fangfang Zhang
          • Número de telefone: +86 777 3682222
      • Wuzhou, Guangxi, China, 543099
        • Recrutamento
        • Wuzhou Gongren Hospital
        • Contato:
          • Jun Yang
          • Número de telefone: +86 774 2036883
      • Yulin, Guangxi, China, 537099
        • Recrutamento
        • The First People's Hospital of Yulin
        • Contato:
          • Na Li
          • Número de telefone: +86 775 2683288
        • Contato:
          • Qingjuan Zhao
    • Jiangsu
      • Suzhou, Jiangsu, China, 215000
        • Recrutamento
        • Lixiang Eye Hospital of Soochow University
        • Contato:
          • Yinbin Tang
          • Número de telefone: +86 512 69359692

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Individuals with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is included in the initial differential diagnosis at participating clinical centers. Each participant contributes only one clinical episode to the primary diagnostic accuracy cohort.

Descrição

Inclusion Criteria:

  1. Individuals presenting with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is considered a reasonable differential diagnosis by the treating clinical team at the initial clinical assessment and before final diagnostic adjudication.
  2. Symptom onset of the current episode within 90 days before enrollment.

Exclusion Criteria:

1. The participant has previously been enrolled in this study. Each participant may be enrolled only once.

A history of optic neuritis or recurrent optic neuropathy before the current episode is not an exclusion criterion.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Suspected Optic Neuritis Differential-Diagnosis Cohort

Individuals with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis at initial clinical assessment. Participants undergo routine clinical evaluation, with study data collected using a structured case report form. The 2022 International Criteria for Optic Neuritis are evaluated alone and with the antibody-stratified adjunct. No treatment is assigned by the study.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis
Prazo: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, of the 2022 International Criteria for Optic Neuritis against Stage 2 full-information expert adjudication. Definite optic neuritis is index-positive and not optic neuritis is index-negative. Possible optic neuritis and indeterminate reference diagnoses are excluded from this conditional binary analysis and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Diagnostic Yield of Definite Optic Neuritis Classification
Prazo: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Among participants with optic neuritis according to Stage 2 full-information expert adjudication, the proportion classified as definite optic neuritis by the 2022 International Criteria for Optic Neuritis. Possible optic neuritis and not optic neuritis classifications remain in the denominator.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the Antibody-Stratified Adjunct in Participants With Aquaporin-4 Immunoglobulin G Positivity or Clear-Positive Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
Prazo: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Among participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the 3-month index window, diagnostic performance of the 2022 criteria alone and with the adjunct will be compared against Stage 2 full-information expert adjudication. Sensitivity, specificity, predictive values, and likelihood ratios with 95 percent confidence intervals will use the conditional and low-threshold definitions specified for the full-cohort comparison. Results will be reported for this subgroup overall and separately by antibody type. Definite-classification yield and reference diagnoses of newly upgraded cases will also be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the Low-Threshold 2022 Criteria Definition
Prazo: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, when definite or possible optic neuritis is index-positive and not optic neuritis is index-negative under the 2022 criteria. Stage 2 full-information expert adjudication is the reference standard. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis With the Antibody-Stratified Adjunct
Prazo: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment

In the full cohort, performance of the 2022 criteria with the adjunct will be compared with the original criteria against Stage 2 full-information expert adjudication. In the conditional analysis, definite optic neuritis is positive and not optic neuritis is negative; possible optic neuritis is excluded. In the low-threshold analysis, definite or possible optic neuritis is positive and not optic neuritis is negative. Sensitivity, specificity, predictive values, likelihood ratios, and 95 percent confidence intervals will be reported. Definite-classification yield will also be compared in the same reference-positive participants, retaining possible classifications as not definite. Reference diagnoses of newly upgraded cases will be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations but reported separately.

Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
Proportion of Indeterminate Reference-Standard Diagnoses
Prazo: Up to 6 Months After Enrollment

Proportion of participants assessed by the Stage 2 full-information expert adjudication panel whose reference-standard diagnosis is indeterminate.

Up to 6 Months After Enrollment
Distribution of 2022 International Criteria for Optic Neuritis Classifications
Prazo: Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset

Proportion of participants classified as definite optic neuritis, possible optic neuritis, or not optic neuritis by the 2022 International Criteria for Optic Neuritis.

Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset
Change in Expert-Adjudicated Diagnosis After Disclosure of Aquaporin-4 Immunoglobulin G and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
Prazo: Paired adjudications using baseline and follow-up information available up to 6 months after enrollment

Among participants with at least one aquaporin-4 immunoglobulin G or myelin oligodendrocyte glycoprotein immunoglobulin G result available within the reference-standard information window and completed adjudications at both stages, the proportion whose diagnosis changes after disclosure. The direction of change between optic neuritis, non-optic neuritis, and indeterminate diagnoses will be reported, overall and by antibody status. Participants with neither antibody result available, or with an adjudication missing at either stage, are excluded from this proportion and reported separately. Diagnostic change is not assumed to represent correction of an error.

Paired adjudications using baseline and follow-up information available up to 6 months after enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Yi Du, MD, PhD, First Affiliated Hospital of Guangxi Medical University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de janeiro de 2025

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de janeiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

11 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de maio de 2026

Primeira postagem (Real)

3 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified participant-level data and a data dictionary will be made available to qualified researchers upon reasonable request after publication of the main diagnostic accuracy results, subject to ethics approval, institutional approval, and execution of a data use agreement.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever